Innoviva (INVA) Non Operating Investment Income (2020 - 2023)
Innoviva's (INVA) quarterly Non Operating Investment Income came in at $22.7 million in Q3 2023, up 355.52% YoY from $5.0 million in Q3 2022, and up 355.52% on a QoQ basis from -$8.9 million in Q3 2022.
Analysis
Innoviva (INVA) Non Operating Investment Income (2020 - 2023) Analysis & Trends
Innoviva (INVA) has 4 years of Non Operating Investment Income data on file, last reported at $22.7 million in Q3 2023.
- Quarterly Non Operating Investment Income rose 355.52% year-over-year to $22.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$54.2 million (down 194.95% YoY) and the FY2024 annual result came in at -$5.3 million, down 120.83% from the prior year.
- Non Operating Investment Income climbed to $22.7 million in Q3 2023, from -$8.9 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $134.0 million in Q3 2021 to a low of -$58.6 million in Q2 2022.
- A 4-year average of $16.5 million and a median of $21.9 million in 2020 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2021 — Non Operating Investment Income surged 556.19% — and 2022, when it tumbled 229.32%.
- Tracing INVA's Non Operating Investment Income over 4 years: stood at -$38.1 million in 2020, then jumped by 451.65% to $134.0 million in 2021, then sank by 106.63% to -$8.9 million in 2022, then jumped by 355.52% to $22.7 million in 2023.
- The last three Non Operating Investment Income figures came in at $22.7 million (Q3 2023), -$8.9 million (Q3 2022), and -$58.6 million (Q2 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 22.70 Mn |
| Sep 30, 2022 | -67.88 Mn |
| Jun 30, 2022 | -58.60 Mn |
| Mar 31, 2022 | -9.41 Mn |
| Sep 30, 2021 | 133.97 Mn |
| Jun 30, 2021 | 45.32 Mn |
| Mar 31, 2021 | 55.05 Mn |
| Dec 31, 2020 | 11.03 Mn |
| Sep 30, 2020 | -29.37 Mn |
| Jun 30, 2020 | 46.70 Mn |
| Mar 31, 2020 | 21.92 Mn |